CVRx, Inc. (CVRX) stock intrinsic value fair value estimate & owner earnings analysis

CVRx sells Barostim, an implanted device that stimulates the pressure sensors in the carotid artery to treat heart failure with reduced ejection fraction. Revenue comes from per-implant sales to hospitals: $39.3 million in 2023, $51.3 million in 2024 and $56.7 million in 2025 (1,648 U.S. and 219 European units), at an 85% gross margin. About 92% of sales are in the United States through a direct sales force (53 territories and 252 active implanting centers at the end of 2025). First-half 2026 revenue was $30.5 million, up 17%, but in August the company lowered its full-year outlook, citing turnover in its sales force and friction with insurers; its chief revenue officer has since left and a new chief financial officer started on October 12, 2026. A shareholder owning more than 5% has publicly urged the board to sell the company. The earnings record. The business has never produced cash from its operations. Operating cash flow was a use of $27.7 million (2021), $42.7 million (2022), $39.0 million (2023), $39.1 million (2024), $40.2 million (2025) and $21.0 million in the first half of 2026. Treating stock compensation as a real cost ($11.1 million in 2025; 2024's $19.1 million includes about $8.4 million from modifying a retiring CEO's options), removing working-capital swings and deducting only the capital spending needed to maintain the business (under $1.4 million a year), owner earnings were a loss of $2.80, $2.01, $1.95, $2.66 and $2.02 per share for 2021 through 2025. Adding back cash interest paid ($5.0 million in 2025, $2.7 million in the first half of 2026) to see the business before its lender, the loss is about $1.80 to $2.65 per share each year; our reference level is a loss of about $2.00 per share, the middle of every year since the 2021 public listing. Revenue growth has not narrowed this loss: in 2025 gross profit of $48.3 million was overwhelmed by $11.1 million of research and development and $88.5 million of selling, general and administrative cost. The 2025 loss per share was about 24% smaller than 2024's only because the one-time option charge did not repeat; no improvement is credited in year 1 of any case. Debt and cash. At June 30, 2026 the company held $64.6 million of cash against $60.0 million of Innovatus term loans plus a $2.7 million final payment due May 2031. A January 9, 2026 amendment deferred principal: interest only through January 2030, then 16 monthly payments of about $3.8 million. Interest floats at the greater of prime or 6.75%, plus 2.65% (at least 9.4%), so the loan costs well above a bond rate for its life; we add about $8.5 million to what is owed for that excess cost. The loan is secured by substantially all of the company's personal property, carries prepayment penalties, forbids dividends, and requires trailing-twelve-month revenue of at least 50% of the Board-approved plan. Further draws of $15 million (2027) and $25 million (2028) require market values of $190 million and $300 million, conditions we do not credit. A $50 million at-the-market share program was set up in January 2026. At the first-half 2026 burn of about $21 million per six months (our extrapolation), cash would last about 18 months from June 30 before new capital is needed. Growth credited. None. Revenue growth is real, but it has been paid for with outside money, it depends on new territories, insurer coverage (Category I physician billing codes finalized for 2026; a Devoted Health Medicare Advantage policy effective July 2026) and a sales force that has just turned over, and it has never yet lowered the cash loss. By our arithmetic revenue would need to roughly double with cash costs held nearly flat for owner earnings to turn positive. Bear case: about -$0.80 per share. The company keeps losing roughly $21 million every six months, the revised 2026 plan is missed, and the lender accelerates the loan around the end of 2026, or new money is available only at a price that leaves existing holders a negligible stake. Business worth: nothing as a going concern. Owes: $62.7 million of principal and final payment plus a prepayment penalty, against roughly $43 million of cash after a second half like the first. Difference: roughly $21 million more owed than held, so the company would owe more than it is worth and shareholders would be left with nothing. The lender's security over nearly all assets is the structural fact behind this case. Base case: about -$0.25 per share. Business worth: nothing credited, because the operating business consumes about $2.00 per share a year before interest and no path to profit is secured. Owes: $62.7 million plus about $8.5 million of excess interest cost, about $71 million, against $64.6 million of cash. Difference: about $6.6 million more owed than held, so on the latest balance sheet the company appears to owe slightly more than it is worth, and that gap widens with every quarter of losses until new capital is raised, which would dilute current owners. Bull case: about $0.40 per share. The company's own levers work: revenue grows 14% a year for ten years (below the 2024 and first-half 2026 pace, above 2025's), cash operating costs rise 5% a year, gross margin holds at 85% and stock compensation stays near $11 million. On those assumptions the business still loses cash for eight years (about $50 million in 2027, near breakeven by 2034), turns positive in year 9 and reaches about $22 million a year by year 10, which is held flat thereafter. Business worth: about $18 million today after those losses. Owes: about $6.6 million more than its cash. Difference: about $11 million, or $0.40 per share on 26.5 million diluted shares, and that assumes the roughly $250 million of cumulative losses before breakeven can be funded without selling shares at depressed prices, which the record does not support. A sale of the company to a larger device maker, as one shareholder has urged, is not modeled in any case because no process or offer has been announced. What changed since the previous analysis. Little in the business: the company appointed a new CFO effective October 12, 2026 and a shareholder has called for a sale. This review states the bear and base cases as negative figures to show plainly that, on the latest balance sheet, the company owes about as much as or more than its cash and the business itself is not producing value; the previous figures are not comparable on that point. Margin of safety price: not set. We are confident about the earnings level, a loss of about $2.00 per share before interest, because it has stayed between $1.80 and $2.70 in every year since 2021. The worst plausible outcome, a covenant breach or a financing on punitive terms within about 18 months, leaves shareholders with nothing, and the business structure (a single product, a secured lender with a claim on nearly all assets, dependence on insurers' coverage decisions) would not protect them. If we are wrong about growth stalling the shares are worth nothing; if we are wrong in the favorable direction the best evidenced outcome is well under $1 per share before any dilution. The company pays no dividend and consumes about $42 million a year while an owner waits. There is no price at which a 20% annual return can be supported by facts we can point to today, so no margin of safety price is given.